Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Cabergoline 4mg tablets
0409010U0AAACAC
|
Cabergoline (Parkinsonism) | Cabergoline | Central Nervous System | No data available |
|
Cafergot suppositories
0407041F0BFAAAH
|
Cafergot | Ergotamine tartrate | Central Nervous System | No data available |
|
Cafergot tablets
0407041F0BFABAM
|
Cafergot | Ergotamine tartrate | Central Nervous System | No data available |
|
Caffeine citrate 100mg/5ml oral solution
0404000E0AAAJAJ
|
Caffeine citrate | Caffeine citrate | Central Nervous System | No data available |
|
Caffeine citrate 10mg/1ml solution for infusion ampoules
0404000E0AAAXAX
|
Caffeine citrate | Caffeine citrate | Central Nervous System | No data available |
|
Caffeine citrate 10mg/5ml oral liquid
0404000E0AAAMAM
|
Caffeine citrate | Caffeine citrate | Central Nervous System | No data available |
|
Caffeine citrate 16mg/5ml oral solution
0404000E0AAAWAW
|
Caffeine citrate | Caffeine citrate | Central Nervous System | No data available |
|
Caffeine citrate 180mg/5ml oral liquid
0404000E0AAATAT
|
Caffeine citrate | Caffeine citrate | Central Nervous System | No data available |
|
Caffeine citrate 200mg/5ml oral liquid
0404000E0AAAPAP
|
Caffeine citrate | Caffeine citrate | Central Nervous System | No data available |
|
Caffeine citrate 20mg/1ml solution for infusion ampoules
0404000E0AAALAL
|
Caffeine citrate | Caffeine citrate | Central Nervous System | No data available |
|
Caffeine citrate 25mg/5ml oral liquid
0404000E0AAAQAQ
|
Caffeine citrate | Caffeine citrate | Central Nervous System | No data available |
|
Caffeine citrate 80mg/5ml oral solution
0404000E0AAASAS
|
Caffeine citrate | Caffeine citrate | Central Nervous System | No data available |
|
CalCold Six Plus oral solution
0407010X0CTAABM
|
Calcold (Paracetamol combined) | Paracetamol combined preparations | Central Nervous System | No data available |
|
Calpol Infant 120mg/5ml oral suspension 5ml sachets
0407010H0BEASDJ
|
Calpol | Paracetamol | Central Nervous System | No data available |
|
Calpol Night oral solution
0407010X0CUAABM
|
Calpol (Paracetamol combined) | Paracetamol combined preparations | Central Nervous System | No data available |
|
Calpol Paediatric 120mg/5ml oral suspension sugar free
0407010H0BEAIAW
|
Calpol | Paracetamol | Central Nervous System | No data available |
|
Calpol Six Plus 250mg/5ml oral suspension
0407010H0BEALAC
|
Calpol | Paracetamol | Central Nervous System | No data available |
|
Candox 10mg modified-release tablets
0407020ADBGAAAF
|
Candox | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Candox 20mg modified-release tablets
0407020ADBGABAG
|
Candox | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Candox 40mg modified-release tablets
0407020ADBGADAH
|
Candox | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Candox 5mg modified-release tablets
0407020ADBGACAK
|
Candox | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Candox 80mg modified-release tablets
0407020ADBGAEAI
|
Candox | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Cannabidiol 25mg/ml oral solution sugar free
0408010AMAAABAB
|
Cannabidiol | Cannabidiol | Central Nervous System | No data available |
|
Caprin 300mg gastro-resistant tablets
0407010B0BBABA3
|
Caprin (Analgesic) | Aspirin | Central Nervous System | No data available |
|
Carbamazepine 10mg/5ml oral liquid
0408010C0AABGBG
|
Carbamazepine | Carbamazepine | Central Nervous System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.